Form 8-K
8-K — Adaptive Biotechnologies Corp
Accession: 0001193125-26-271117
Filed: 2026-06-15
Period: 2026-06-15
CIK: 0001478320
SIC: 2836 (BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES))
Item: Other Events
Item: Financial Statements and Exhibits
Documents
8-K — d65233d8k.htm (Primary)
EX-99.1 (d65233dex991.htm)
EX-99.2 (d65233dex992.htm)
EX-99.3 (d65233dex993.htm)
XML — IDEA: XBRL DOCUMENT (R1.htm)
8-K
8-K (Primary)
Filename: d65233d8k.htm · Sequence: 1
8-K
Adaptive Biotechnologies Corp false 0001478320 0001478320 2026-06-15 2026-06-15
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 15, 2026
ADAPTIVE BIOTECHNOLOGIES CORPORATION
(Exact name of Registrant as Specified in Its Charter)
Washington
001-38957
27-0907024
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
1665 Eastlake Avenue East, Suite 200,
Seattle, Washington
98102
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: (206) 659-0067
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol(s)
Name of each exchange
on which registered
Common stock, par value $0.0001 per share
ADPT
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01.
Other Events.
On June 15, 2026, Adaptive Biotechnologies Corporation (the “Company”) issued a press release announcing that it intends to offer, subject to market conditions and other factors, $250 million in aggregate principal amount of convertible senior notes due 2031 (the “Notes”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Offering”). The Company expects to grant a 13-day option to the initial purchasers of the Notes to purchase up to an additional $37.5 million aggregate principal amount of the Notes. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Also on June 15, 2026, the Company issued a second press release announcing its intention to pursue a separation of its Minimal Residual Disease (MRD) and Immune Medicine businesses (the “Business Separation”). A copy of the press release is attached hereto as Exhibit 99.2 and incorporated herein by reference.
In addition to the press release relating to the Business Separation and in connection with the Offering, the Company is issuing a statement providing additional information relating to the Business Separation, which is attached as Exhibit 99.3 and incorporated herein by reference.
Neither this Current Report on Form 8-K nor the press releases or additional information incorporated herein constitutes an offer to sell, or the solicitation of an offer to buy, the Notes or the shares of the Company’s common stock, if any, issuable upon conversion of the Notes.
Item 9.01.
Financial Statements and Exhibits.
(d) Exhibits.
Exhibit
Number
Description
99.1
Press Release dated June 15, 2026 (Notes Offering)
99.2
Press Release dated June 15, 2026 (Business Separation)
99.3
Company Statement
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Adaptive Biotechnologies Corporation
Date: June 15, 2026
By:
/s/ Kyle Piskel
Kyle Piskel
Chief Financial Officer
EX-99.1
EX-99.1
Filename: d65233dex991.htm · Sequence: 2
EX-99.1
Exhibit 99.1
Adaptive Biotechnologies Corporation Announces Proposed Convertible Senior Notes Offering
•
Proceeds expected to be deployed to repay the OrbiMed Purchase Agreement to enhance financial
flexibility
•
Additional proceeds used to pay for the capped call with a premium of at least 75% and to repurchase up to
$25 million of common stock to reduce potential dilution
•
Remaining capital to be used for general corporate purposes and opportunistic initiatives in the MRD
business
SEATTLE—(GLOBE NEWSWIRE)—June 15, 2026—Adaptive Biotechnologies Corporation (“Adaptive
Biotechnologies”) (Nasdaq: ADPT) today announced its intention to offer, subject to market and other conditions, $250 million aggregate principal amount of convertible senior notes due 2031 (the “notes”) in a private offering
to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Adaptive Biotechnologies also expects to grant the initial purchasers of the
notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $37.5 million aggregate principal amount of notes.
The notes will be senior, unsecured obligations of Adaptive Biotechnologies, will accrue interest payable semi-annually in arrears and will mature on
July 1, 2031, unless earlier repurchased, redeemed or converted. Noteholders will have the right to convert their notes in certain circumstances and during specified periods. Adaptive Biotechnologies will settle conversions by paying or
delivering, as applicable, cash, shares of its common stock or a combination of cash and shares of its common stock, at Adaptive Biotechnologies’s election.
The notes will be redeemable, in whole or in part (subject to certain limitations), for cash at Adaptive Biotechnologies’s option at any time, and from
time to time, on or after July 1, 2029 and on or before the 40th scheduled trading day immediately before the maturity date, but only if the last reported sale price per share of Adaptive Biotechnologies’s common stock exceeds 130% of the
conversion price for a specified period of time and certain other conditions are satisfied. In addition, the notes will be redeemable, in whole and not in part, at Adaptive Biotechnologies’s option at any time, if the aggregate principal
amount of the notes that remain outstanding is less than 15% of the aggregate principal amount of notes initially issued under the indenture and certain other conditions are satisfied. The redemption price will be equal to the principal amount of
the notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date.
If certain corporate events that constitute a
“fundamental change” occur, then, subject to a limited exception, noteholders may require Adaptive Biotechnologies to repurchase their notes for cash. The repurchase price will be equal to the principal amount of the notes to be
repurchased, plus accrued and unpaid interest, if any, to, but excluding, the applicable repurchase date.
The interest rate, initial conversion rate and
other terms of the notes will be determined at the pricing of the offering.
- 1 -
Adaptive Biotechnologies intends to use a portion of the net proceeds from the offering to fund the cost of
entering into the capped call transactions described below. Adaptive Biotechnologies expects to use up to $25 million of the net proceeds from the offering to repurchase shares of its common stock concurrently with the pricing of the offering
in privately negotiated transactions effected through one of the initial purchasers of the notes or its affiliate, as Adaptive Biotechnologies’s agent. Adaptive Biotechnologies intends to use the remainder of the net proceeds from the offering
for the repayment of the OrbiMed Purchase Agreement, general corporate purposes and opportunistic initiatives in the MRD business. If the initial purchasers exercise their option to purchase additional notes, then Adaptive Biotechnologies intends to
use a portion of the additional net proceeds to fund the cost of entering into additional capped call transactions as described below. The concurrent repurchases of shares of Adaptive Biotechnologies’s common stock described above may result
in Adaptive Biotechnologies’s common stock trading at prices that are higher than would be the case in the absence of these repurchases, which may result in a higher initial conversion price for the notes Adaptive Biotechnologies is offering.
In connection with the pricing of the notes, Adaptive Biotechnologies has been advised that J. Wood Capital Advisors LLC (“JWCA”), Adaptive
Biotechnologies’s financial advisor with respect to the offering, intends to purchase up to $10 million of shares of common stock concurrently with the offering in privately negotiated transactions with institutional investors through one
of the initial purchasers or its affiliate (the “JWCA Purchase”).
In connection with the pricing of the notes, Adaptive Biotechnologies
expects to enter into privately negotiated capped call transactions with one or more of the initial purchasers or their affiliates or one or more other financial institutions (the “option counterparties”). The capped call transactions
are expected to cover, subject to anti-dilution adjustments substantially similar to those applicable to the notes, the number of shares of Adaptive Biotechnologies’s common stock that will initially underlie the notes. If the initial
purchasers exercise their option to purchase additional notes, then Adaptive Biotechnologies expects to enter into additional capped call transactions with the option counterparties.
The capped call transactions are expected generally to reduce the potential dilution to Adaptive Biotechnologies’s common stock upon any conversion of
the notes and/or offset any potential cash payments Adaptive Biotechnologies is required to make in excess of the principal amount of converted notes, as the case may be, upon conversion of the notes. If, however, the market price per share of
Adaptive Biotechnologies’s common stock, as measured under the terms of the capped call transactions, exceeds the cap price of the capped call transactions, there would nevertheless be dilution and/or there would not be an offset of such
potential cash payments, in each case, to the extent that such market price exceeds the cap price of the capped call transactions.
In connection with
establishing their initial hedges of the capped call transactions, the option counterparties or their respective affiliates expect to enter into various derivative transactions with respect to Adaptive Biotechnologies’s common stock and/or
purchase shares of Adaptive Biotechnologies’s common stock concurrently with or shortly after the pricing of the notes. This activity, as well as the JWCA Purchase, could increase (or reduce the size of any decrease in) the market price of
Adaptive Biotechnologies’s common stock or the notes at that time.
- 2 -
In addition, the option counterparties or their respective affiliates may modify their hedge positions by
entering into or unwinding various derivatives with respect to Adaptive Biotechnologies’s common stock and/or purchasing or selling Adaptive Biotechnologies’s common stock or other securities of Adaptive Biotechnologies in secondary
market transactions following the pricing of the notes and prior to the maturity of the notes (and (x) are likely to do so during any observation period related to a conversion of notes or following any repurchase of notes by Adaptive
Biotechnologies in connection with any fundamental change and (y) may do so following any repurchase of notes by Adaptive Biotechnologies other than in connection with any fundamental change). This activity, as well as the JWCA Purchase, could
also cause or avoid an increase or decrease in the market price of Adaptive Biotechnologies’s common stock or the notes, which could affect the ability to convert the notes, and, to the extent the activity occurs during any observation period
related to a conversion of notes, it could affect the number of shares and value of the consideration that noteholders will receive upon conversion of the notes.
The offer and sale of the notes and any shares of common stock issuable upon conversion of the notes have not been, and will not be, registered under the
Securities Act or any other securities laws, and the notes and any such shares cannot be offered or sold except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any other
applicable securities laws. This press release does not constitute an offer to sell, or the solicitation of an offer to buy, the notes or any shares of common stock issuable upon conversion of the notes, nor will there be any sale of the notes or
any such shares, in any state or other jurisdiction in which such offer, sale or solicitation would be unlawful.
About Adaptive Biotechnologies
Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent
biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has
prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to
partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business segments: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the
diagnosis, monitoring, and treatment of diseases such as cancer and autoimmune disorders. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.
Forward-Looking Statements
This press release includes
forward-looking statements, including statements regarding the anticipated terms of the notes being offered, the completion, timing and size of the proposed offering, the intended use of the proceeds and the anticipated terms of, and the effects of
entering into, the capped call transactions described above. Forward-looking statements represent Adaptive Biotechnologies’s current expectations regarding future events and are subject to known and
- 3 -
unknown risks and uncertainties that could cause actual results to differ materially from those implied by the forward-looking statements. Among those risks and uncertainties are market
conditions, including market interest rates, the trading price and volatility of Adaptive Biotechnologies’s common stock and risks relating to Adaptive Biotechnologies’s business, including those described in periodic reports that
Adaptive Biotechnologies files from time to time with the SEC. Adaptive Biotechnologies may not consummate the proposed offering described in this press release and, if the proposed offering is consummated, cannot provide any assurances regarding
the final terms of the offering or the notes or its ability to effectively apply the net proceeds as described above. The forward-looking statements included in this press release speak only as of the date of this press release, and Adaptive
Biotechnologies does not undertake to update the statements included in this press release for subsequent developments, except as required by law.
Contact Information
Karina Calzadilla, Vice President,
Investor Relations and FP&A
201-396-1687
investors@adaptivebiotech.com
Erica Jones, Associate Corporate
Communications Director
206-279-2423
media@adaptivebiotech.com
- 4 -
EX-99.2
EX-99.2
Filename: d65233dex992.htm · Sequence: 3
EX-99.2
Exhibit 99.2
Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses
MRD has scaled into a profitable, category-leading MRD diagnostics business, while
Immune Medicine has built a differentiated discovery platform powered by proprietary immune data and AI
SEATTLE, June 15, 2026 (GLOBE NEWSWIRE) – Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial-stage biotechnology company focused on
translating the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced its intention to pursue a separation of its Minimal Residual Disease (MRD) and Immune Medicine businesses. The company is
evaluating strategic and structural alternatives for Immune Medicine to support its growth strategy, capital needs, and value creation opportunities outside of Adaptive, and expects to identify its preferred path to separation by year-end 2026.
Since establishing MRD and Immune Medicine as separate operating segments under Adaptive in 2024, both
businesses have continued to advance. MRD has achieved significant scale, expanded reimbursement, strengthened its clinical evidence base and reached profitability, establishing clonoSEQ® as a
leading platform in MRD testing.
At the same time, Immune Medicine has continued to build a uniquely differentiated discovery platform anchored by the
world’s largest clinically linked immune receptor dataset and enhanced by advances in AI-driven discovery. The platform is increasingly demonstrating its potential to generate novel biological insights,
identify therapeutic targets, and accelerate the development of precision medicines. As Immune Medicine enters its next phase of growth, the company believes the value of its differentiated assets may be best realized outside of a diagnostic
commercial model.
“When we completed our strategic review in 2024, we decided to continue developing both MRD and Immune Medicine within Adaptive
while increasing their operational independence,” said Chad Robins, Chief Executive Officer and Co-Founder of Adaptive Biotechnologies. “The progress achieved by both businesses has reinforced that
decision. As we look ahead, Adaptive will focus on expanding its leadership in MRD diagnostics, while pursuing the optimal path for Immune Medicine outside of Adaptive. We believe this separation is the best way to unlock the full potential of both
businesses, increasing their impact on patients and creating long-term value for shareholders.”
About the MRD business
Adaptive’s MRD business has achieved significant scale, profitability and expanded clinical utility. Revenue has grown from $103 million in 2023 to
$212 million in 2025 and the business has reported $15 million in 2025 adjusted EBITDA (non-GAAP). With more than 300 million covered lives, over 175 EMR integrated accounts and greater than 180
active biopharma trials, clonoSEQ is increasingly embedded in routine clinical practice and drug development.
About the Immune Medicine business
Immune Medicine has progressed its data and drug discovery capabilities to uncover causal immune drivers to enable precision medicine in autoimmune
diseases. With over 6 million functional T-cell receptor (TCR)-antigen pairs and well-characterized data sets on more than 10,000 patients, Immune Medicine is discovering pathogenic TCRs and the
disease-causing antigens they bind.
There can be no assurance that this process will result in any transaction or other outcome, or as to the timing or
terms of any such transaction. Adaptive does not intend to disclose further developments unless and until it determines that further disclosure is appropriate or required.
Forward-Looking Statements
This press release contains
forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking
statements, including statements regarding Adaptive’s business strategies, strategic focus, review of strategic alternatives for Immune Medicine, potential sale, separation, partnership, licensing transaction or other strategic or operational
outcome involving Immune Medicine, the timing and outcome of any strategic review process, the growth, profitability, reimbursement, clinical adoption and commercial opportunity of the MRD business, the market opportunity for clonoSEQ, expected
margin expansion, disciplined capital allocation, company-wide profitability and plans and objectives for future operations.
In some cases,
forward-looking statements can be identified by words such as “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,”
“anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” “focus,” “opportunity,”
“evaluate,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.
These statements involve risks, uncertainties and other factors that may cause actual results, levels of
activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under “Risk Factors,”
“Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents Adaptive files with the Securities and Exchange Commission from time to time. Adaptive cautions that
forward-looking statements are based on a combination of facts and factors currently known to the company and projections of the future, about which Adaptive cannot be certain. As a result, the forward-looking statements may not prove to be
accurate. The forward-looking statements in this press release represent Adaptive’s views as of the date hereof. Adaptive undertakes no obligation to update any forward-looking statements for any reason, except as required by law.
ADAPTIVE INVESTORS
Karina Calzadilla, Vice President,
Investor Relations and FP&A
201-396-1687
investors@adaptivebiotech.com
ADAPTIVE MEDIA
Erica Jones, Associate Corporate Communications Director
206-279-2423
media@adaptivebiotech.com
EX-99.3
EX-99.3
Filename: d65233dex993.htm · Sequence: 4
EX-99.3
Exhibit 99.3
In connection with its previous announcements regarding the planned separation of its Immune Medicine businesses and the launch of a convertible notes
offering, Adaptive Biotechnologies Inc. (“we,” “us” and “our”) is providing this statement.
Recent Developments
Separation of Immune Medicine Business
Since establishing MRD and Immune Medicine as separate operating segments in 2024, both businesses have continued to advance. MRD has achieved significant
scale, expanded reimbursement, strengthened its clinical evidence base and reached profitability, establishing clonoSEQ® as a leading platform in MRD clinical and biopharma testing.
At the same time, Immune Medicine has continued to build a uniquely differentiated discovery platform anchored by the world’s largest clinically linked
immune receptor dataset and enhanced by advances in AI-driven discovery. The platform is increasingly demonstrating its potential to generate novel biological insights, identify therapeutic targets, and
accelerate the development of precision medicines. Immune Medicine has progressed its data and drug discovery capabilities to uncover causal immune drivers to enable precision medicine in autoimmune diseases. With over 6 million functional TCR-antigen pairs and well-characterized data sets on more than 10,000 patients, Immune Medicine is discovering pathogenic TCRs and the disease-causing antigens they bind.
As Immune Medicine enters its next phase of growth, we believe the long-term potential of its differentiated assets may be best realized outside of a
diagnostic commercial model. As a result, we have reached an inflection point where we believe separating the businesses would enable each to pursue its distinct strategic priorities, capital requirements, and growth opportunities.
Following a separation, Adaptive would continue as the MRD business, building on its leadership position in MRD diagnostics and biopharma testing. We are
evaluating strategic and structural alternatives for Immune Medicine to pursue its growth strategy, capital needs, and value creation opportunities outside of Adaptive, and expect to identify our preferred path to separation by year end. We believe
this path offers the greatest opportunity to unlock the full potential of both businesses and create long-term value for shareholders.
Leadership for
Immune Medicine, where Dr. Harlan Robins, our Chief Scientific Officer, has been primarily focused, will be determined as its strategic alternatives become clearer. Additionally, in line with his continued obligations to Adaptive and as
approved by our board of directors, Dr. Robins formed a new data-sharing, cloud-computing company, where he is the founder and a director but not a paid employee. As the strategy for Immune Medicine is finalized, the allocation of
Dr. Robins’ time may change. Executive leadership for Adaptive and the MRD business remains intact, and Dr. Robins continues to support research and development efforts for the MRD business.
Repayment of OrbiMed Purchase Agreement
In September 2022, we entered into a revenue interest purchase agreement (the “OrbiMed Purchase Agreement”) with OrbiMed Royalty & Credit
Opportunities IV, LP (“OrbiMed”), an affiliate of OrbiMed Advisors LLC, as collateral agent and administrative agent for the purchasers party thereto (the “Purchasers”). Pursuant to the OrbiMed Purchase Agreement, we received
$124.4 million from the Purchasers (the “Purchaser Payment”), net of expenses. As consideration for such payments, the Purchasers have a right to receive certain revenue interest payments from us each quarter based on a current rate
of five percent of all GAAP revenue, subject to adjustment in September 2028 as provided in the OrbiMed Purchase Agreement. OrbiMed will be entitled to 100% of the revenue interest payments until it has received a total cumulative value of 165% of
the Purchaser Payment (the “Return Cap”), unless full repayment of the amount of the Return Cap has not been made by September 12, 2032, in which case the Return Cap shall be increased to 175% of the Purchaser Payment. To secure our
obligations under the OrbiMed Purchase Agreement, we and our subsidiaries have granted OrbiMed a security interest in our core platform technology assets, subject to certain customary exclusions, as defined in the OrbiMed Purchase Agreement.
OrbiMed has waived various covenants in the OrbiMed Purchase Agreement that otherwise would have restricted our ability to conduct this offering and agreed to
allow us to repay the Purchaser Payment at a Return Cap of 156%, which results in a payoff amount of $156.9 million. We intend to repay this amount using the proceeds from this offering, and then to terminate the OrbiMed Purchase
Agreement.
Risks Relating to our Business
We may not realize the anticipated benefits of separating our Immune Medicine business from our MRD business.
As our Immune Medicine business enters its next phase of growth, we believe the long-term potential of its differentiated assets may be best realized outside
of a diagnostic commercial model of our MRD business. However, we may not achieve the anticipated operational, financial, strategic and other benefits of the separation. If strategic and structural alternatives for Immune Medicine do not emerge, we
may not succeed in separating it from our MRD business, and any alternatives that do become available to us may have commercially challenging terms. Even if we do separate our Immune Medicine business, it may be unable to access the required
capital, personnel, technology, or other resources necessary for the businesses to separately pursue its growth opportunities. Whether or not the separation is successful, pursuing the separation may distract our management, require time and
resources, or adversely impact our operations, employee retention and morale, customer and partner retention, and other important relationships. As a result, we may not realize the anticipated benefits of separating our Immune Medicine business
from our MRD business.
Forward-Looking Statements
This statement includes forward-looking statements, including statements regarding the separation of the Immune Medicine business, repayment of the OrbiMed
Purchase Agreement, completion of the offering, and the expected amount and intended use of the net proceeds described above. Forward-looking statements represent Adaptive Biotechnologies’ current expectations regarding future events and are
subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those implied by the forward-looking statements. Among those risks and uncertainties are market conditions, the satisfaction of the
closing conditions related to the offering and risks relating to Adaptive Biotechnologies’ business, including those described in periodic reports that Adaptive Biotechnologies files from time to time with the Securities and
Exchange Commission. Adaptive Biotechnologies may not consummate the separation of the Immune Medicine business, repayment of the OrbiMed Purchase Agreement, and the offering described in this
statement. The forward-looking statements included in this press release speak only as of the date of this press release, and Adaptive Biotechnologies does not undertake to update the statements included in this press release for subsequent
developments, except as required by law.
XML — IDEA: XBRL DOCUMENT
XML
Filename: R1.htm · Sequence: 9
v3.26.1
Document and Entity Information
Jun. 15, 2026
Cover [Abstract]
Entity Registrant Name
Adaptive Biotechnologies Corp
Amendment Flag
false
Entity Central Index Key
0001478320
Document Type
8-K
Document Period End Date
Jun. 15, 2026
Entity Incorporation State Country Code
WA
Entity File Number
001-38957
Entity Tax Identification Number
27-0907024
Entity Address, Address Line One
1665 Eastlake Avenue East
Entity Address, Address Line Two
Suite 200
Entity Address, City or Town
Seattle
Entity Address, State or Province
WA
Entity Address, Postal Zip Code
98102
City Area Code
(206)
Local Phone Number
659-0067
Written Communications
false
Soliciting Material
false
Pre Commencement Tender Offer
false
Pre Commencement Issuer Tender Offer
false
Security 12b Title
Common stock, par value $0.0001 per share
Trading Symbol
ADPT
Security Exchange Name
NASDAQ
Entity Emerging Growth Company
false
X
- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details
Name:
dei_AmendmentFlag
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Area code of city
+ References
No definition available.
+ Details
Name:
dei_CityAreaCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Cover page.
+ References
No definition available.
+ Details
Name:
dei_CoverAbstract
Namespace Prefix:
dei_
Data Type:
xbrli:stringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
No definition available.
+ Details
Name:
dei_DocumentPeriodEndDate
Namespace Prefix:
dei_
Data Type:
xbrli:dateItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details
Name:
dei_DocumentType
Namespace Prefix:
dei_
Data Type:
dei:submissionTypeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine1
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Address Line 2 such as Street or Suite number
+ References
No definition available.
+ Details
Name:
dei_EntityAddressAddressLine2
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the City or Town
+ References
No definition available.
+ Details
Name:
dei_EntityAddressCityOrTown
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details
Name:
dei_EntityAddressPostalZipCode
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the state or province.
+ References
No definition available.
+ Details
Name:
dei_EntityAddressStateOrProvince
Namespace Prefix:
dei_
Data Type:
dei:stateOrProvinceItemType
Balance Type:
na
Period Type:
duration
X
- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityCentralIndexKey
Namespace Prefix:
dei_
Data Type:
dei:centralIndexKeyItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityEmergingGrowthCompany
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details
Name:
dei_EntityFileNumber
Namespace Prefix:
dei_
Data Type:
dei:fileNumberItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details
Name:
dei_EntityIncorporationStateCountryCode
Namespace Prefix:
dei_
Data Type:
dei:edgarStateCountryItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityRegistrantName
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details
Name:
dei_EntityTaxIdentificationNumber
Namespace Prefix:
dei_
Data Type:
dei:employerIdItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Local phone number for entity.
+ References
No definition available.
+ Details
Name:
dei_LocalPhoneNumber
Namespace Prefix:
dei_
Data Type:
xbrli:normalizedStringItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
+ Details
Name:
dei_PreCommencementIssuerTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
+ Details
Name:
dei_PreCommencementTenderOffer
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details
Name:
dei_Security12bTitle
Namespace Prefix:
dei_
Data Type:
dei:securityTitleItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details
Name:
dei_SecurityExchangeName
Namespace Prefix:
dei_
Data Type:
dei:edgarExchangeCodeItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14a
-Subsection 12
+ Details
Name:
dei_SolicitingMaterial
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details
Name:
dei_TradingSymbol
Namespace Prefix:
dei_
Data Type:
dei:tradingSymbolItemType
Balance Type:
na
Period Type:
duration
X
- Definition
Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
+ Details
Name:
dei_WrittenCommunications
Namespace Prefix:
dei_
Data Type:
xbrli:booleanItemType
Balance Type:
na
Period Type:
duration